Success Metrics

Clinical Success Rate
66.7%

Based on 2 completed trials

Completion Rate
67%(2/3)
Active Trials
3(38%)
Results Posted
100%(2 trials)
Terminated
1(13%)

Phase Distribution

Ph phase_2
4
50%
Ph phase_3
1
13%
Ph phase_1
3
38%

Phase Distribution

3

Early Stage

4

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
3(37.5%)
Phase 2Efficacy & side effects
4(50.0%)
Phase 3Large-scale testing
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

2 of 4 finished

Non-Completion Rate

50.0%

2 ended early

Currently Active

3

trials recruiting

Total Trials

8

all time

Status Distribution
Active(3)
Completed(2)
Terminated(2)
Other(1)

Detailed Status

Active, not recruiting3
Completed2
Withdrawn1
Terminated1
unknown1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
3
Success Rate
66.7%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (37.5%)
Phase 24 (50.0%)
Phase 31 (12.5%)

Trials by Status

completed225%
withdrawn113%
terminated113%
active_not_recruiting338%
unknown113%

Recent Activity

3 active trials
Showing 5 of 8
active_not_recruitingphase_1

TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer

NCT03955978
completedphase_1

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

NCT03307785
active_not_recruitingphase_1

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

NCT02817633
completedphase_2

A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer

NCT03574779
active_not_recruitingphase_2

TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation

NCT03833479
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03955978Phase 1

TSR-042 in Addition to Standard of Care Definitive Radiation for Inoperable Endometrial Cancer

Active Not Recruiting
NCT03307785Phase 1

Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042

Completed
NCT02817633Phase 1

A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Active Not Recruiting
NCT03574779Phase 2

A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer

Completed
NCT03833479Phase 2

TSR-042 as Maintenance Therapy for Patients With High-risk Locally Advanced Cervical Cancer After Chemo-radiation

Active Not Recruiting
NCT04274023Phase 2

Study on TSR-042 in Advanced Clear Cell Sarcoma

Terminated
NCT03016338Phase 2

Study of Niraparib and TSR-042 in Recurrent Endometrial Cancer

Unknown
NCT03806049Phase 3

Trial Comparing Niraparib-bevacizumab-Dostarlimab and Niraparib-bevacizumab to Standard of Care in Recurrent Ovarian Cancer

Withdrawn

All 8 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
8